全文获取类型
收费全文 | 2221篇 |
免费 | 135篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 52篇 |
妇产科学 | 50篇 |
基础医学 | 282篇 |
口腔科学 | 47篇 |
临床医学 | 200篇 |
内科学 | 506篇 |
皮肤病学 | 74篇 |
神经病学 | 290篇 |
特种医学 | 58篇 |
外科学 | 379篇 |
综合类 | 11篇 |
预防医学 | 151篇 |
眼科学 | 21篇 |
药学 | 91篇 |
中国医学 | 7篇 |
肿瘤学 | 113篇 |
出版年
2023年 | 15篇 |
2022年 | 40篇 |
2021年 | 58篇 |
2020年 | 36篇 |
2019年 | 62篇 |
2018年 | 56篇 |
2017年 | 47篇 |
2016年 | 51篇 |
2015年 | 58篇 |
2014年 | 72篇 |
2013年 | 124篇 |
2012年 | 156篇 |
2011年 | 118篇 |
2010年 | 74篇 |
2009年 | 72篇 |
2008年 | 101篇 |
2007年 | 110篇 |
2006年 | 104篇 |
2005年 | 103篇 |
2004年 | 124篇 |
2003年 | 94篇 |
2002年 | 78篇 |
2001年 | 58篇 |
2000年 | 61篇 |
1999年 | 45篇 |
1998年 | 20篇 |
1997年 | 18篇 |
1996年 | 16篇 |
1995年 | 4篇 |
1994年 | 15篇 |
1993年 | 5篇 |
1992年 | 43篇 |
1991年 | 33篇 |
1990年 | 29篇 |
1989年 | 34篇 |
1988年 | 37篇 |
1987年 | 35篇 |
1986年 | 17篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 16篇 |
1982年 | 12篇 |
1981年 | 9篇 |
1979年 | 11篇 |
1978年 | 9篇 |
1977年 | 5篇 |
1976年 | 5篇 |
1973年 | 5篇 |
1972年 | 4篇 |
1969年 | 4篇 |
排序方式: 共有2364条查询结果,搜索用时 31 毫秒
21.
Can Ki67 immunostaining predict response to radiotherapy in oral squamous cell carcinoma? 总被引:1,自引:2,他引:1
下载免费PDF全文
![点击此处可从《Journal of clinical pathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
G Valente R Orecchia S Gandolfo M Arnaudo R Ragona S Kerim G Palestro 《Journal of clinical pathology》1994,47(2):109-112
AIMS--To determine whether immunohistochemical evaluation of the abatement of proliferating cells after a first course of radiotherapy could predict the final response to treatment in oral squamous cell carcinoma (SCC). METHODS--Frozen sections from 31 cases of histologically confirmed oral SCC were stained with the monoclonal antibody Ki67 at diagnosis and after 10 Gy of radiotherapy. The percentage difference of Ki67 positive cells among the biopsy specimens taken at the beginning and after 10 Gy was correlated with the clinical response obtained at the end of the treatment and its significance determined. RESULTS--The percentage of Ki67 positive cells at diagnosis had no significant correlation with the final therapeutic result of radiotherapy. By contrast, the 32% difference of proliferating cells after 10 Gy of radiotherapy significantly differentiated responders from non-responders (p < 0.05). Furthermore, the abatement of the growth fraction after 10 Gy of radiotherapy was significantly correlated with the complete response (p < 0.01). CONCLUSIONS--These data show that the immunohistochemical evaluation of the abatement of Ki67 positive cells after 10 Gy of radiotherapy provides an independent variable of responsiveness to radiotherapy, allowing a reliable prediction of the final therapeutic result to be made. 相似文献
22.
23.
Morse MA Garst J Osada T Khan S Hobeika A Clay TM Valente N Shreeniwas R Sutton MA Delcayre A Hsu DH Le Pecq JB Lyerly HK 《Journal of translational medicine》2005,3(1):9-8
BACKGROUND: There is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC). METHODS: This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals. RESULTS: Thirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1-2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52-665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4. CONCLUSION: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors. 相似文献
24.
Novelli A Valente EM Bernardini L Ceccarini C Sinibaldi L Caputo V Cavalli P Dallapiccola B 《European journal of human genetics : EJHG》2004,12(7):579-583
Brody disease is a rare muscle disorder characterized by exercise-induced impairment in muscle relaxation, due to a markedly reduced influx of calcium ions in the sarcoplasmic reticulum. A subset of autosomal recessive families harbour mutations in the ATP2A1 gene, encoding the fast-twitch skeletal muscle sarcoplasmic reticulum Ca(2+) ATPase (SERCA1). Rare autosomal dominant families have been described, in which ATP2A1 was excluded as the causative gene, further supporting genetic heterogeneity. We report four individuals from a three-generation Italian family with a clinical phenotype of Brody disease, in which linkage analysis excluded ATP2A1 as the responsible gene. The disease cosegregates in an autosomal dominant fashion with an apparently balanced constitutional chromosome translocation (2;7)(p11.2;p12.1), suggesting a causal relationship between the rearrangement and the phenotype. FISH analysis using YAC and PAC clones as probes refined the breakpoint regions to genomic segments of about 164 and 120 kb, respectively, providing a possible clue to pinpoint the location of a novel gene responsible for this rare muscle disorder. 相似文献
25.
Dina Ruano António Macedo Maria Jo?o Soares José Valente Maria Helena Azevedo Carlos Pato Mara Helena Hutz Clarissa S Gama Maria Inês Lobato Paulo Belmonte-de-Abreu Peter Heutink Joana Almeida Palha 《American journal of medical genetics. Part B, Neuropsychiatric genetics》2007,(5):642-646
Several observations point to the involvement of disturbed lipid biology in schizophrenia. Reduced response to niacin flushing test, which involves vasodilatation induced by prostaglandin D2 (PGD2), is among the evidences, together with decreased CSF levels of lipocalin-type prostaglandin D2 synthase (PTGDS), the enzyme responsible for the synthesis of PGD2 in the brain. Since PTGDS is also a carrier for lipophilic molecules such as retinoids and thyroid hormones, altered PTGDS levels might influence both PGD2-mediated signaling, and vitamin A and thyroid hormone availability. To test whether genetic variants of PTGDS are involved in the etiology of schizophrenia, we searched for variants in the coding and regulatory regions of the gene. We identified four previously described polymorphisms. Using two case-control samples from Portugal and Brazil, none of the polymorphisms tested was associated with the disease. In addition, no transmission distortion was observed in an independent parents-offspring sample from the Azorean Islands. Our data do not support the involvement of the PTGDS gene in the etiology of schizophrenia. 相似文献
26.
Molecular diagnosis of myocarditis and dilated cardiomyopathy in children: clinicopathologic features and prognostic implications. 总被引:6,自引:0,他引:6
27.
28.
Screening of thalassaemia carriers in intermediate school of Latium: results of four years'' work. 总被引:1,自引:2,他引:1
下载免费PDF全文
![点击此处可从《Journal of medical genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
E Silvestroni I Bianco B Graziani C Carboni M Valente M Lerone S U D''Arca 《Journal of medical genetics》1980,17(3):161-164
From 1975 to 1979 the Rome Microcythaemia Centre carried out four health education campaigns and thalassaemia screenings among students of the intermediate schools throughout Latium, under the auspices and with the financial support of the Health Authorities of the Latium region. This project is aimed at avoiding reproduction by pairs of thalassaemia carriers and the birth of homozygous children. During the four campaigns 138 501 students were examined, that is, 70 to 76% of those enrolled. Of these 3343 were found to be thalassaemic. Thus the overall prevalence of thalassaemia in Latium is 2.41%, with minor fluctuations from one province to another and, above all, a slight, though definite, trend towards higher values in the southern part of Latium bordering on Campania. The screening was welcomed by the population and the thalassaemic families, there were no detectable negative side-effects, and it resulted in an increased awareness of the problem of the thalassaemias. 相似文献
29.
Escudier B Dorval T Chaput N André F Caby MP Novault S Flament C Leboulaire C Borg C Amigorena S Boccaccio C Bonnerot C Dhellin O Movassagh M Piperno S Robert C Serra V Valente N Le Pecq JB Spatz A Lantz O Tursz T Angevin E Zitvogel L 《Journal of translational medicine》2005,3(1):10-13
BACKGROUND: DC derived-exosomes are nanomeric vesicles harboring functional MHC/peptide complexes capable of promoting T cell immune responses and tumor rejection. Here we report the feasability and safety of the first Phase I clinical trial using autologous exosomes pulsed with MAGE 3 peptides for the immunization of stage III/IV melanoma patients. Secondary endpoints were the monitoring of T cell responses and the clinical outcome. PATIENTS AND METHODS: Exosomes were purified from day 7 autologous monocyte derived-DC cultures. Fifteen patients fullfilling the inclusion criteria (stage IIIB and IV, HLA-A1+, or -B35+ and HLA-DPO4+ leukocyte phenotype, tumor expressing MAGE3 antigen) were enrolled from 2000 to 2002 and received four exosome vaccinations. Two dose levels of either MHC class II molecules (0.13 versus 0.40 x 1014 molecules) or peptides (10 versus 100 mug/ml) were tested. Evaluations were performed before and 2 weeks after immunization. A continuation treatment was performed in 4 cases of non progression. RESULTS: The GMP process allowed to harvest about 5 x 1014 exosomal MHC class II molecules allowing inclusion of all 15 patients. There was no grade II toxicity and the maximal tolerated dose was not achieved. One patient exhibited a partial response according to the RECIST criteria. This HLA-B35+/A2+ patient vaccinated with A1/B35 defined CTL epitopes developed halo of depigmentation around naevi, a MART1-specific HLA-A2 restricted T cell response in the tumor bed associated with progressive loss of HLA-A2 and HLA-BC molecules on tumor cells during therapy with exosomes. In addition, one minor, two stable and one mixed responses were observed in skin and lymph node sites. MAGE3 specific CD4+ and CD8+ T cell responses could not be detected in peripheral blood. CONCLUSION: The first exosome Phase I trial highlighted the feasibility of large scale exosome production and the safety of exosome administration. 相似文献
30.
E A Dellers P T Valente P R Edmonds G Balsara 《Archives of pathology & laboratory medicine》1991,115(9):918-920
Mixed mesodermal tumors are uncommon outside the uterus. Nine extrauterine mixed mesodermal tumors (eight ovarian and one extragenital) were selected for histochemical and immunoperoxidase study. In eight cases, both epithelial and mesenchymal elements were malignant (chondroid in six, rhabdomyoid in four, and osteoid in two). One ovarian tumor was an adenosarcoma. All cases were stained with periodic acid-Schiff with and without diastase and for alpha 1-antitrypsin, myoglobin, keratin, vimentin, muscle-specific actin, and alpha 1-antichymotrypsin, by using the avidin-biotin-immunoperoxidase method. The periodic acid-Schiff-positive, diastase-resistant droplets in several of the tumors showed peripheral alpha 1-antitrypsin positivity. Keratin delineated epithelial areas well in seven cases, and rhabdomyoid differentiation was confirmed with myoglobin in four cases. However, squamous elements in one tumor were falsely positive for myoglobin. We concluded that despite occasional cross-reactivity, carefully interpreted immunoperoxidase stains can be useful in distinguishing epithelial and mesenchymal elements in these tumors. 相似文献